Renewable Chemical Innovator Capra Biosciences to Build a Green Biochemical Production Facility in Manassas, Virginia
24 avr. 2023 09h00 HE
|
Capra Biosciences
MANASSAS, Va., April 24, 2023 (GLOBE NEWSWIRE) -- Capra Biosciences is scaling up their novel bioreactor technology to produce sustainable chemicals in Northern Virginia. This project was funded...
Cell and Gene Therapy Biomanufacturing Market, 2031
19 avr. 2023 06h03 HE
|
Research and Markets
Dublin, April 19, 2023 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Type, Application, Usage, End-user, and Region -...
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
12 avr. 2023 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Liberation Labs Secures $30 Million in Equipment Funding for First Biomanufacturing Facility
12 avr. 2023 07h00 HE
|
Liberation Labs
RICHMOND, Ind., April 12, 2023 (GLOBE NEWSWIRE) -- Liberation Labs, industrial biotech’s fabrication partner, has secured $30 million in equipment financing to advance development of its first...
Dyadic to Present at World Vaccine Congress Washington 2023
30 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Reports 2022 Year End Results and Recent Company Progress
29 mars 2023 16h00 HE
|
Dyadic International, Inc.
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding...
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
15 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing
11 mars 2023 07h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca...
BioP2P Network Names Scientific Advisory Board to Guide Efforts to Fuel Growing U.S. Bioeconomy
08 mars 2023 05h15 HE
|
California Biomanufacturing Center
VACAVILLE, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- The BioProcess to Product (BIOP2P) Network, a national program to accelerate the transformation of manufacturing in the United States for the...
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
01 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...